Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. RESULTS: After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. CONCLUSIONS: Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combinations of VEGF-targeted agents with anti-PD-1 have demonstrated clinical benefi ts in endometrial carcinoma (pembrolizumab plus lenvatinib; refs.69, 70 ), RCC (pembrolizumab plus axitinib; nivolumab plus cabozantinib; avelumab plus axitinib), and hepatocellular carcinoma (atezolizumab plus bevacizumab; refs.[71][72][73][74][75].”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [71]
In the citing paper
“One study suggested that ICI-colitis correlated with particular strains of microbial flora colonization,19”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Self-citationMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133 · cited 1×
“IMDC risk score is determined by the total number of the following six risk factors that are present: Karnofsky performance-status score of less than 80 (on a scale from 0 to 100, with lower scores indicating greater disability(12)), a time from initial diagnosis to randomization of less than 1 year, a hemoglobin leve…”
MethodSelf-citationKarnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517 · cited 1×
“Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.(12) The programmed death ligand 1 (PD-L1) combined positive score was calculated as the number of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells, multip…”
MethodSystemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Self-citationEscudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Self-citationSternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Self-citation
Research works printed but not linked: 1
- Noone AM, Howlader N, Krapcho M, et al., eds. SEER cancer statistics review (CSR), 1975-2015. Bethesda, MD: National Cancer Institute, 2018 (https://seer .cancer .gov/ csr/ 1975_2015/ ).
Cited by
Items 501–600 of 1,002
NCCN Guidelines Updates: Management of Metastatic Kidney Cancer.
Jonasch, E. (2019) · PubMed · doi:10.6004/jnccn.2019.5008 · Cited by 46
Yu, P., Zhu, C., You, X., Gu, W., Wang, X., Wang, Y., Bu, R., & Wang, K. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06837-w · Cited by 50
“As expected, the ORR was 59.3% in the pembrolizumab + axitinib group and 35.7% in the sunitinib group, with a mPFS of 15.1 months and 11.1 months, respectively [39].”
InfluentialRenal cancer: signaling pathways and advances in targeted therapies
Jiang, A., Li, J., He, Z., Liu, Y., Qiao, K., Fang, Y., Qu, L., Luo, P., Lin, A., & Wang, L. (2024) · MedComm · doi:10.1002/mco2.676 · Cited by 51
Su, X., Li, J., Xu, X., Ye, Y., Wang, C., Pang, G., Liu, W., Liu, A., Zhao, C., & Hao, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05552-6 · Cited by 49
“…in combination with axitinib for the treatment of advanced RCC, after a median follow-up of 12.8 months, the estimated percentage of patients alive at 12 months was 89.9% in the pembrolizumab plus axitinib group and 78.3% in the sunitinib group (HR, 0.53; 95% CI 0.38–0.74; P < 0.0001) [14].”
BackgroundInfluentialDufies, M., Verbiest, A., Cooley, L. S., Ndiaye, P. D., Viotti, J., He, X., Nottet, N., Souleyreau, W., Hagege, A., Torrino, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01653-w · Cited by 46
Self-citationKlümper, N., Ralser, D. J., Zarbl, R., Schlack, K., Schrader, A. J., Rehlinghaus, M., Hoffmann, M. J., Niegisch, G., Uhlig, A., Trojan, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002949 · Cited by 47
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Maritaz, C., Broutin, S., Chaput, N., Marabelle, A., & Paci, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01182-3 · Cited by 52
“These results were confirmed by the phase III KEYNOTE-426 trial of pembrolizumab at 200 mg Q3W in combination with axitinib [77].”
ResultSantoni, M., Massari, F., Myint, Z. W., Iacovelli, R., Pichler, M., Basso, U., Kopecký, J., Kucharz, J., Buti, S., Rizzo, M., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00978-2 · Cited by 48
Cooley, L. S., Rudewicz, J., Souleyreau, W., Emanuelli, A., Álvarez-Arenas, A., Clarke, K., Falciani, F., Dufies, M., Lambrechts, D., Modave, E., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01416-5 · Cited by 44
Ghoreifi, A., Vaishampayan, U. N., Yin, M., Psutka, S. P., & Djaladat, H. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5269 · Cited by 44
Kwon, M., Kim, C. G., Lee, H., Cho, H., Kim, Y., Lee, E. C., Choi, S. J., Park, J., Seo, I., Bogen, B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0267 · Cited by 48
“blockade with conventional chemotherapy or targeted therapy has enhanced clinical efficacy in clinical trials for patients with non–small cell lung cancer (30) or renal cell carcinoma (31).”
BackgroundMcIntosh, A. G., Umbreit, E. C., Holland, L. C., Gu, C., Tannir, N. M., Matin, S. F., Karam, J. A., Culp, S. H., & Wood, C. G. (2020) · Cancer · doi:10.1002/cncr.32991 · Cited by 44
Epaillard, N., Simonaggio, A., Elaidi, R., AZZOUZ, F., Braychenko, E., Thibault, C., Sun, C., Moreira, M., Oudard, S. M., & Vano, Y. A. (2020) · Bulletin du Cancer · doi:10.1016/s0007-4551(20)30283-6 · Cited by 46
Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy
Ragavan, M. V., & Das, M. S. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00762-8 · Cited by 49
A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy
Duru, G., van Egmond, M., & Heemskerk, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584723 · Cited by 48
Curkovic, N. B., Bai, K., Ye, F., & Johnson, D. B. (2024) · Cancers · doi:10.3390/cancers16020340 · Cited by 50
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma
Santoni, M., Mollica, V., Rizzo, A., & Massari, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102881 · Cited by 47
Labadie, B. W., Liu, P., Bao, R., Crist, M., Fernandes, R., Ferreira, L., Graupner, S., Poklepovic, A. S., Durán, I., Vareki, S. M., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-02144-7 · Cited by 45
“In previously untreated metastatic ccRCC, anti-PD1/L1 antibodies combined with VEGFR2 TKI is emerging [7, 8].”
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
Sun, J., Zheng, Y., Mamun, M., Li, X., Chen, X., & Gao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110504 · Cited by 51
lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System
Barth, D. A., Juráček, J., Slabý, O., Pichler, M., & Calin, G. A. (2020) · Cancers · doi:10.3390/cancers12082148 · Cited by 47
“Nonetheless, the introduction of immune checkpoint inhibitors such as nivolumab, pembrolizumab and combinations with antiangiogenetic agents in the treatment of ccRCC drastically improved the outcome of metastatic RCC [5,56].”
Backgroundvan der Beek, J. N., Hol, J. A., L’Herminé, A. C., Graf, N. M., van Tinteren, H., Pritchard‐Jones, K., Houwing, M. E., de Krijger, R. R., Vujanic, G. M., Dzhuma, K., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33476 · Cited by 43
Möller, K., Fraune, C., Blessin, N. C., Lennartz, M., Kluth, M., Hube‐Magg, C., Lindhorst, L., Dahlem, R., Fisch, M., Eichenauer, T., et al. (2021) · International Urology and Nephrology · doi:10.1007/s11255-021-02841-7 · Cited by 47
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC
Turco, F., Tucci, M., Stefano, R. F. D., Samuelly, A., Bungaro, M., Audisio, M., Pisano, C., Maïo, M. D., Scagliotti, G. V., & Buttigliero, C. (2021) · Endocrine Related Cancer · doi:10.1530/erc-20-0457 · Cited by 50
Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors
Chambers, A., Kundranda, M. N., Rao, S. K., Mahmoud, F. A., & Niu, J. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01099-7 · Cited by 48
Tucker, M. D., Brown, L. C., Chen, Y., Kao, C., Hirshman, N. A., Kinsey, E. N., Ancell, K. K., Beckermann, K. E., Davis, N. B., McAlister, R. K., et al. (2021) · Biomarker Research · doi:10.1186/s40364-021-00334-4 · Cited by 44
Self-citationLiu, W., Ren, D., Xiong, W., Jin, X., & Zhu, L. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02253-0 · Cited by 45
“Recently, immune checkpoint inhibitors (ICIs) alone and in combination with TKIs have been shown to be beneficial for the survival of mRCC patients and have been approved for first-line or second-line treatment of mRCC [10, 11].”
BackgroundLombardi, P., Filetti, M., Falcone, R., Bidino, R. D., Iacovelli, R., Ciccarese, C., Bria, E., Tortora, G., Scambia, G., & Daniele, G. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102377 · Cited by 46
Beckermann, K. E., Patnaik, A., Winer, I. S., Tan, W. W., Bashir, B., Kyriakopoulos, C. E., Sweis, R. F., Chamberlain, M. C., & Rini, B. I. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01419-1 · Cited by 42
Self-citationMartini, D. J., Liu, Y., Shabto, J. M., Carthon, B. C., Hitron, E., Russler, G. A., Caulfield, S. E., Kissick, H. T., Harris, W. B., Küçük, Ö., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0578 · Cited by 42
Dudek, A. Z., Liu, L. C., Gupta, S., Logan, T. F., Singer, E. A., Joshi, M., Zakharia, Y., Lang, J. M., Schwarz, J. K., Al-Janadi, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02394 · Cited by 46
Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review
van der Beek, J. N., Geller, J. I., de Krijger, R. R., Graf, N. M., Pritchard‐Jones, K., Drost, J., Verschuur, A. C., Murphy, D., Ray, S., Spreafico, F., et al. (2020) · Cancers · doi:10.3390/cancers12071776 · Cited by 44
Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
Bomze, D., Asher, N., Ali, O. H., Flatz, L., Azoulay, D., Markel, G., & Meirson, T. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.17675 · Cited by 47
Lan, C., Zhao, J., Yang, F., Xiong, Y., Li, R., Huang, Y., Wang, J., Liu, C., Bi, X., Jin, H., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100689 · Cited by 50
Carlisle, J. W., Jansen, C. S., Cardenas, M. A., Sobierajska, E., Reyes, A. M., Greenwald, R., del Balzo, L., Prokhnevska, N., Küçük, Ö., Carthon, B. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004803 · Cited by 46
State of the Art: Multidisciplinary Management of Oligometastatic Renal Cell Carcinoma
Dason, S., Lacuna, K. P., Hannan, R., Singer, E. A., & Runcie, K. D. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390038 · Cited by 41
Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions
Rafii, S., Mukherji, D., Komaranchath, A. S., Khalil, C., Iqbal, F., Abdelwahab, S. İ., Abyad, A. M., Abuhelwa, A. Y., Gandikota, L., & Al-Shamsi, H. O. (2025) · Cancers · doi:10.3390/cancers17172898 · Cited by 48
Antibody-lectin chimeras for glyco-immune checkpoint blockade
Stark, J. C., Gray, M. A., Ibarlucea-Benitez, I., Lustig, M., Bond, A., Cho, B., Govil, I., Luu, T., Priestley, M. J., Veth, T. S., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02884-6 · Cited by 54
Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
Garces, A. I., Au, L., Mason, R., Thomas, J. M., & Larkin, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1649657 · Cited by 42
Graham, J., Shah, A. Y., Wells, J. C., McKay, R. R., Vaishampayan, U. N., Hansen, A. R., Donskov, F. N., Bjarnason, G. A., Beuselinck, B., de Velasco, G., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.11.001 · Cited by 42
Kawashima, A., Kanazawa, T., Kidani, Y., Yoshida, T., Hirata, M., Nishida, K., Nojima, S., Yamamoto, Y., Kato, T., Hatano, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63060-1 · Cited by 44
Wang, C., Li, M., Wei, R., & Wu, J. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100332 · Cited by 45
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
Tripathi, A., Lin, E., Xie, W., Flaifel, A., Steinharter, J. A., Gatof, E. S., Bouchard, G., Fleischer, J. H., Chanzá, N. M., Gray, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001467 · Cited by 44
Basso, U., Facchinetti, A., Rossi, E. M. C., Maruzzo, M., Conteduca, V., Aieta, M., Massari, F., Fraccon, A. P., Mucciarini, C., Sava, T., et al. (2021) · The Oncologist · doi:10.1002/onco.13842 · Cited by 41
“TKIs are synergic with immunotherapy, and combination regimens can be given to patients in all risk groups [2].”
BackgroundClinical implications of isolated troponinemia following immune checkpoint inhibitor therapy
Delombaerde, D. L., Vervloet, D., Franssen, C., Croes, L., Gremonprez, F., Prenen, H., Peeters, M., & Vulsteke, C. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100216 · Cited by 44
“For example, the combination of ICIs with targeted therapies, such as tyrosine kinase inhibitors, has already been investigated and resulted in an enhanced efficacy in advanced renal cell carcinoma and BRAF-mutant melanoma.(50,51) However, drug-induced cardiotoxicity has been described for both therapeutic classes and…”
BackgroundSerzan, M. T., & Atkins, M. B. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.76 · Cited by 45
Self-citationNew approaches to first-line treatment of advanced renal cell carcinoma
George, D. J., Lee, C., & Heng, D. Y. C. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211034708 · Cited by 43
“PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer
Bell, H. N., Cotta, B. H., Salami, S. S., Kim, H. L., & Vaishampayan, U. N. (2021) · Kidney Cancer · doi:10.3233/kca-210010 · Cited by 42
“Keynote 426 [9] and Javelin-101 [10] enrolled 17% and 13% non-nephrectomy patients, respectively.”
BackgroundHasanov, E., Yeboa, D. N., Tucker, M. D., Swanson, T. A., Beckham, T. H., Rini, B. I., Ene, C., Hasanov, M., Derks, S. H. A. E., Smits, M., et al. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21729 · Cited by 55
Self-citationImmunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes, D. M., Frey, A. E., Prsic, E. H., Tran, T. T. T., Clune, J. E., Sznol, M., Kluger, H. M., Forman, H. P., Becher, R. D., Olino, K. L., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2023.6025 · Cited by 42
Revisiting the biological role of the Warburg effect: Evolving perspectives on cancer metabolism
León-Oliva, D. D., González-Prieto, P., Castro-Martinez, P. D., Boaru, D. L., Hernandez, P. L., Fraile‐Μartinez, O., Montero, C. G., Guijarro, L. G., López-González, L., Díaz, R., et al. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156151 · Cited by 50
Debien, V., Thouvenin, J., Lindner, V., Barthélémy, P., Lang, H., Flippot, R., & Malouf, G. G. (2019) · Cancers · doi:10.3390/cancers12010099 · Cited by 41
“Notably, nivolumab plus ipilimumab [47] and pembrolizumab plus axitinib [48] have both demonstrated improved OS in intermediate/poor risk patients and all comers, respectively, while atezolizumab plus bevacizumab [37]”
BackgroundNishio, S., Matsumoto, K., Takehara, K., Kawamura, N., Hasegawa, K., Takeshima, N., Aoki, D., Kamiura, S., Arakawa, A., Kondo, E., et al. (2020) · Cancer Science · doi:10.1111/cas.14340 · Cited by 43
“The median (range) age was 61 (25-89) years for the overall population and 57 (37-78) years for Japanese patients (Table 1).”
BackgroundLarcher, A., Fallara, G., Rosiello, G., Re, C., Baiamonte, G., Agnesi, S., Cignoli, D., Colandrea, G., Basile, G., Briganti, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.05.014 · Cited by 41
Chau, V., & Bilušić, M. (2020) · Cancer Management and Research · doi:10.2147/cmar.s216605 · Cited by 46
Gan, C. L., Dudani, S., Wells, J. C., Donskov, F. N., Pal, S. K., Dizman, N., Rathi, N., Beuselinck, B., Yan, F., Lalani, A. A., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.3717 · Cited by 40
Wiele, A. J., Bathala, T. K., Hahn, A. W., Xiao, L., Duran, M., Ross, J. A., Jonasch, E. W., Shah, A. Y., Campbell, M. T., Msaouel, P., et al. (2021) · The Oncologist · doi:10.1002/onco.13770 · Cited by 46
Akhbariyoon, H., Azizpour, Y., Esfahani, M. F., Firoozabad, M. S. M., Rad, M. R., Esfahani, K. S., Khoshavi, N., Karimi, N., Shirinisaz, A., Abedi, F., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108873 · Cited by 41
Iinuma, K., Enomoto, T., Kawada, K., Fujimoto, S., Ishida, T., Takagi, K., Nagai, S., Ito, H., Kawase, M., Nakai, C., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225325 · Cited by 41
“In other recent randomized phase III trials (Checkmate 214 [4], KEYNOTE-426 [5], JAVELIN Renal 101 [6], IMmotion151 [7], and CheckMate 9ER [8]), combining ICI and/or TKI therapies reportedly affords greater clinical benefits, especially in terms of oncological outcomes, than NIVO or TKI monotherapy…”
Dong, K., Chen, W., Pan, X., Wang, H., Sun, Y., Qian, C., Chen, W., Wang, C., Fu, Y., & Cui, X. (2022) · BMC Cancer · doi:10.1186/s12885-022-09251-7 · Cited by 44
“Clinical trials of immune checkpoint inhibitor (ICI) versus TKI treatment for ccRCC, such as CheckMate 214 (5), CheckMate 9ER (6), Keynote-426 (7), and IMmotion 151 (8) have shown pronounced clinical bene ts.”
MethodChoi, S. H., Yoo, S. S., Lee, S. Y., & Park, J. Y. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01382-6 · Cited by 41
Aldin, A., Besiroglu, B., Adams, A., Monsef, I., Piechotta, V., Tomlinson, E., Hornbach, C., Dressen, N., Goldkuhle, M., Maisch, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013798.pub2 · Cited by 51
Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications
Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E. C., Sinha, Y., Korashy, H. M., & Maccalli, C. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100107 · Cited by 44
Yanagisawa, T., Mori, K., Matsukawa, A., Kawada, T., Katayama, S., Bekku, K., Laukhtina, E., Rajwa, P., Quhal, F., Pradère, B., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03621-1 · Cited by 41
“The results of treatment rankings are summarized in Table 2.”
BackgroundChoueiri, T. K., Merchan, J. R., Figlin, R. A., McDermott, D. F., Arrowsmith, E. R., Michaelson, M. D., Tykodi, S. S., Heath, E. I., Spigel, D. R., D'souza, A., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00649-1 · Cited by 49
Self-citationWei, Y., Du, Q., Jiang, X., Li, L., Li, T., Li, M., Fan, X., Li, Y., Kariminia, S., & Li, Q. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.008 · Cited by 41
Hwang, I., Park, I., Yoon, S., & Lee, J. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.09.009 · Cited by 41
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
Wakabayashi, G., Lee, Y., Luh, F., Kuo, C.-N., Chang, W., & Yen, Y. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0588-8 · Cited by 40
Grimm, M., Leucht, K., Grünwald, V., & Foller, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020565 · Cited by 42
Immune evasion in renal cell carcinoma: biology, clinical translation, future directions
Wang, X., Lopez, R., Luchtel, R. A., Hafizi, S., Gartrell, B. A., & Shenoy, N. K. (2020) · Kidney International · doi:10.1016/j.kint.2020.08.028 · Cited by 43
Yeom, D.-H., Lee, Y.-S., Ryu, I., Lee, S., Sung, B., Lee, H., Kim, D., Ahn, J.-H., Ha, E., Choi, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010241 · Cited by 39
Kamai, T., Kijima, T., Tsuzuki, T., Nukui, A., Abe, H., Arai, K., & Yoshida, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02843-x · Cited by 42
“A study performed in an effort to develop a tolerable and more effective combination regimen of an antiVEGF agent and an anti–PD-1 antibody found improved outcome [22, 23].”
BackgroundProgress Update in Pediatric Renal Tumors
Jain, J., Sutton, K. S., & Hong, A. L. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01016-y · Cited by 39
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data
Barthélémy, P., Rioux-Leclercq, N. C., Thibault, C., Saldana, C., Borchiellini, D., Chevreau, C., Desmoulins, I., Gobert, A., Hilgers, W., Khalil, A., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102191 · Cited by 43
Self-citationImmunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
Kathuria‐Prakash, N., Drolen, C. E., Hannigan, C. A., & Drakaki, A. (2021) · Life · doi:10.3390/life12010024 · Cited by 41
“7%), and these findings were noted across IMDC risk groups and PD-L1 expression groups [34].”
BackgroundInfluentialEvolving landscape of first-line combination therapy in advanced renal cancer: a systematic review
Lalani, A. A., Heng, D. Y. C., Basappa, N. S., Wood, L. A., Iqbal, N., McLeod, D., Soulières, D., & Kollmannsberger, C. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221108685 · Cited by 41
Self-citationBedke, J., Rini, B. I., Plimack, E. R., Stus, V. P., Gafanov, R. A., Waddell, T., Nosov, D., Pouliot, F., Soulières, D., Melichar, B., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.06.009 · Cited by 40
Self-citationAdjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade
Fitzgerald, K. N., Motzer, R. J., & Lee, C. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00666-2 · Cited by 42
Verhoeff, S. R., Oosting, S. F., Elias, S. G., van Es, S. C., Gerritse, S. L., Angus, L., Heskamp, S., Desar, I. M. E., van Oordt, C. W. M. D. H., van der Veldt, A. A. M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0921 · Cited by 41
Alhalabi, O., Thouvenin, J., Négrier, S., Vano, Y. A., Campedel, L., Hasanov, E., Bakouny, Z., Hahn, A. W., Bilen, M. A., Msaouel, P., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyac262 · Cited by 38
Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity
Tzeng, H., & Huang, Y.-J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054422 · Cited by 38
“sunitinib • Longer OS than sunitinib • Higher objective response rate [134] Pembrolizumab PD-1”
BackgroundUpdate on combined immunotherapy for the treatment of advanced renal cell carcinoma
Gebrael, G., Sahu, K. K., Agarwal, N., & Maughan, B. L. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2193528 · Cited by 42
“This study led to the approval of the axitinib/pembrolizumab in patients across all three IMDC risk groups.(5) At the time of initial analysis, with median follow-up of 12.”
ResultImmunotherapies targeting tumor vasculature: challenges and opportunities
Dianat-Moghadam, H., Nedaeinia, R., Keshavarz, M., Azizi, M., Kazemi, M., & Salehi, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1226360 · Cited by 36
“Axitinib (kinase inhibitors) Pembrolizumab (anti-PD1 mAb) Advanced-stage RCC Phase III FDA approved NCT02853331 (67)”
Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic
Lyskjær, I., Iisager, L., Axelsen, C. T., Nielsen, T. K., Dyrskjøt, L., & Fristrup, N. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1892 · Cited by 45
Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma
Barth, D. A., Slabý, O., Klec, C., Juráček, J., Drulă, R., Calin, G. A., & Pichler, M. (2019) · Cancers · doi:10.3390/cancers11101580 · Cited by 38
Tumor Endothelial Cell—A Biological Tool for Translational Cancer Research
Annan, D. A., Kikuchi, H., Maishi, N., Hida, Y., & Hida, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093238 · Cited by 38
Chau, I., Penel, N., Soriano, A. O., Arkenau, H., Cultrera, J. L., Santana-Dávila, R., Calvo, E., Tourneau, C. L., Zender, L., Bendell, J. C., et al. (2020) · Cancers · doi:10.3390/cancers12102985 · Cited by 42
Msaouel, P., Lee, J., & Thall, P. F. (2021) · Cancers · doi:10.3390/cancers13112741 · Cited by 40
Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
Petrelli, F., Morelli, A. M., Luciani, A., Ghidini, A., & Solinas, C. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00824-3 · Cited by 43
Agarwal, N., Azad, A., Carles, J., Chowdhury, S., McGregor, B. A., Merseburger, A. S., Oudard, S. M., Saad, F., Soares, A., Benzaghou, F., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-1096 · Cited by 40
Iacovelli, R., Ciccarese, C., Facchini, G., Milella, M., Urbano, F., Basso, U., Giorgi, U. D., Sabbatini, R., Santini, D., Berardi, R., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00732-y · Cited by 39
Santoni, M., Massari, F., Bracarda, S., Grande, E., Matrana, M. R., Rizzo, M., Giorgi, U. D., Basso, U., Aurilio, G., Incorvaia, L., et al. (2022) · European Urology Focus · doi:10.1016/j.euf.2022.02.004 · Cited by 38
Marona, P., Górka, J., Kwapisz, O., Jura, J., Ryś, J., Hoffman, R. M., & Miękus, K. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05251-4 · Cited by 42
Yu, L., Xu, J., Qiao, R., Han, B., Zhong, H., & Zhong, R. (2022) · Cancer Medicine · doi:10.1002/cam4.5360 · Cited by 43
Chowdhury, S., Infante, J. R., Hawkins, R. E., Voss, M. H., Perini, R. F., Arkenau, H., Voskoboynik, M., Aimone, P., Isabelle, N., Reising, A., et al. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.04.007 · Cited by 59
Self-citationTrial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
Petrazzuolo, A., Maiuri, M. C., Zitvogel, L., Kroemer, G., & Kepp, O. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2077898 · Cited by 41
“1 months.(109,110) Axitinib, yet another multikinase inhibitor, targets VEGFR, PDGFR, KIT, RET, CSF1R and FLT3.”
Liu, D., Liu, L., Zhao, X., Zhang, X., Chen, X., Che, X., & Wu, G. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104702 · Cited by 43
Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Scarpelli, M., Cimadamore, A., Antonio Lopez-beltran, B., Liang Cheng, C., Battelli, N., Montironi, R., et al. (2019) · Cancers · doi:10.3390/cancers11060830 · Cited by 37
“The advent of combinations of immune-checkpoint inhibitors and TKIs provides concrete hope for our patients.”
BackgroundInfluentialRoviello, G., Corona, S. P., Nesi, G., & Mini, E. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919861905 · Cited by 41
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Pozzessere, C., Bassanelli, M., Ceribelli, A., Rasul, S., Li, S., Prior, J. O., & Cicone, F. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0938-9 · Cited by 37
Watson, T. R., Gao, X. Y., Reynolds, K. L., & Kong, C. Y. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.16144 · Cited by 43
Metadata
- Authors
- Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., Vynnychenko, I., Kryzhanivska, A., Bondarenko, I., Azevedo, S. J., Borchiellini, D., Szczylik, C., Markus, M., McDermott, R. S., Bedke, J., Tartas, S., Chang, Y.-H., Tamada, S., Shou, Q., Perini, R. F., Chen, M., Atkins, M. B., & Powles, T.
- Affiliations
- Fox Chase Cancer Center (US)
- From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) — all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Rini, Brian I.
- Plimack, Elizabeth R.
- Stus, Viktor
- Gafanov, Rustem
- Nosov, Dmitry
- Pouliot, Frédéric
- Alekseev, Boris
- Soulières, Denis
- Melichar, Bohuslav
- Vynnychenko, Ihor
- Kryzhanivska, Anna
- Bondarenko, Igor
- Borchiellini, Delphine
- Szczylik, Cezary
- Bedke, Jens
- Tamada, Satoshi
- Perini, Rodolfo F.
- Atkins, Michael B.
- Powles, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-21
- Volume
- 380
- Issue
- 12
- Pages
- 1116-1127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2913745075
- Cited by
- 3,403
- References
- 23
- Citations by year
- 2026: 269 · 2025: 323 · 2024: 431 · 2023: 440 · 2022: 589 · 2021: 597 · 2020: 532 · 2019: 220
- FWCI
- 357.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Oncourology (Russian Society of Oncourologists) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pembrolizumab, axitinib, sunitinib, immune checkpoint inhibitors, PD-1 inhibitors, PD-L1 expression, overall survival, progression-free survival, objective response rate, first-line therapy, adverse events, immune-related adverse events, tyrosine kinase inhibitors, IMDC risk groups
- MeSH terms
- Sunitinib, Axitinib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Survival Rate, Single-Blind Method, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.